PMDA — authorised 26 March 2019
- Marketing authorisation holder: AbbVie Deutschland GmbH & Co KG
- Status: approved
🇯🇵 Skyrizi in Japan
PMDA authorised Skyrizi on 26 March 2019
Marketing authorisation
Skyrizi in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in Japan
Frequently asked questions
Is Skyrizi approved in Japan?
Yes. PMDA authorised it on 26 March 2019.
Who is the marketing authorisation holder for Skyrizi in Japan?
AbbVie Deutschland GmbH & Co KG holds the Japanese marketing authorisation.